Table 3.
SNP | Chr | Gene | Maj | Min | GWAS stage |
Replication |
Meta-analysis |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case Afreq | Cont Afreq | p-value | OR (95% CI) | Case Afreq | Cont Afreq | p-value | OR (95% CI) | p-value | OR (95% CI) | ||||||
Total population | |||||||||||||||
rs371061408a) | 1 | - | T | C | 0.32 | 0.24 | 3.72E-05 | 1.46 (1.22-1.75) | 0.28 | 0.27 | 0.3395 | 1.06 (0.94-1.21) | 0.0017 | 1.18 (1.06-1.31) | |
Male | |||||||||||||||
rs6936644b) | 6 | ZSCAN31 | C | T | 0.49 | 0.48 | 1.81E-05 | 1.56 (1.27-1.90) | 0.44 | 0.48 | 0.3231 | 1.07 (0.93-1.24) | 0.0010 | 1.22 (1.08-1.37) | |
rs7669841b) | 4 | TET2 | G | C | 0.30 | 0.30 | 3.64E-05 | 1.58 (1.27-1.97) | 0.31 | 0.30 | 0.2850 | 0.92 (0.79-1.07) | 0.1405 | 1.10 (0.97-1.24) | |
rs7215433c) | 17 | - | T | C | 0.26 | 0.28 | 3.80E-05 | 0.59 (0.46-0.76) | 0.25 | 0.26 | 0.5488 | 0.95 (0.81-1.12) | 0.0060 | 0.83 (0.72-0.95) | |
Female | |||||||||||||||
rs12233126d) | 2 | EIF5B | T | A | 0.38 | 0.27 | 6.27E-05 | 1.77 (1.34-2.35) | 0.28 | 0.28 | 0.8231 | 1.02 (0.83-1.26) | 0.0109 | 1.24 (1.05-1.46) | |
rs111673703b) | 11 | APLP2 | C | T | 0.11 | 0.05 | 7.08E-05 | 2.49 (1.59-3.91) | 0.07 | 0.06 | 0.6472 | 1.09 (0.75-1.59) | 0.0037 | 1.53 (1.15-2.05) | |
rs10463885 | 5 | CDC42SE2 | A | G | 0.06 | 0.02 | 9.73E-05 | 4.17 (2.03-8.55) | 0.02 | 0.03 | 0.6665 | 0.88 (0.48-1.6) | 0.0289 | 1.68 (1.05-2.66) |
SNP, single-nucleotide polymorphism; GWAS, genome-wide association study; Chr, chromosome; Maj, major allele; Min, minor allele; CaseAfreq, case allele frequency; ContAfreq, control allele frequency; OR, odds ratio; CI, confidence interval; LD, linkage disequilibrium.
8 SNPs were included in the same LD block,
2 SNPs were included in the same LD block,
16 SNPs were included in the same LD block,
5 SNPs were included in the same LD block.